AYTU BIOPHARMA, INC.

AYTU

CIK 0001385818 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$15M
↓-6.5% -$1Mvs FY2024 (Q4)
Operating Income
$9M
↓-6.9% -$690Kvs FY2024 (Q4)
Gross Profit
$10M
↓-10.8% -$1Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Weak
39/100
  • Profitability
    0ROIC -18.1% (10% = solid, 20%+ = moat)
  • Liquidity
    38Current Ratio 1.26 (above 1.5 = solid)
  • Leverage
    71D/E 0.57 (under 0.5 = conservative)
  • Efficiency
    27Asset Turnover 0.55x (1.0+ = capital-efficient)
  • Growth
    0Revenue YoY -6.5% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin -13.0% · trend +5.6pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$86K
investment in PP&E
Stock-based comp (TTM)
$649K
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$122M
everything owned
Total liabilities
$101M
everything owed
Stockholders' equity
$14M
shareholder claim
Net debt
$-20M
Net cash position ($20M)

Recent performance · 65 quarters

Revenue↓-6.5% -$1M
$15M
Net Income↓-1443.1% -$11M
$-11M
Free Cash Flow↑+26.2% +$759K
$4M
Operating Margin↓-2.5pts
-13.0%

Drill down